ArticleJCI insight2016
Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation.
Open access · goldAbstract read
In one paragraph
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Epigenetic regulation and chromatin organization in cystic fibrosis airways.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Review
- IL-22Ra2 Levels Remain Elevated in People with Cystic Fibrosis despite Modulator Therapy.American journal of respiratory and critical care medicine · 2024Article
- Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases.Journal of clinical medicine · 2023Review
- Systems serology in cystic fibrosis: Anti-Pseudomonas IgG1 responses and reduced lung function.Cell reports. Medicine · 2023Article
- BRD4 as a Therapeutic Target in Pulmonary Diseases.International journal of molecular sciences · 2023Review
- Mucosal Immunity in Cystic Fibrosis.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.The Journal of clinical investigation · 2021Article
- RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma.Respiratory research · 2021Article
- The BET family in immunity and disease.Signal transduction and targeted therapy · 2021Review
- Interleukin-36 Cytokines in Infectious and Non-Infectious Lung Diseases.Frontiers in immunology · 2021Review
- Cystic Fibrosis Lung Transplant Recipients Have Suppressed Airway Interferon Responses duringCell reports. Medicine · 2020Article
- PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.Pigment cell & melanoma research · 2020Article
- ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure.Frontiers in immunology · 2020Article
- The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.Pigment cell & melanoma research · 2019Article
- Epigenetic Regulation of IL-17-Induced Chemokines in Lung Epithelial Cells.Mediators of inflammation · 2019Article
- Review
- Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 1 country.
Kong ChenRichard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
Brian T CampfieldRichard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA; University of Pittsburgh, Division of Pediatric Infectious Diseases, Department of Pediatrics, Pittsburgh, Pennsylvania, USA.
Sally E WenzelUniversity of Pittsburgh Asthma Institute at UPMC, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Jeremy P McAleerRichard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
James L KreindlerDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Geoffrey KurlandDivision of Pediatric Pulmonology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Radha GopalRichard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
Ting WangDivision of Pulmonary Medicine, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Wei ChenDivision of Pulmonary Medicine, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Taylor EddensRichard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
Kathleen M QuinnRichard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
Mike M MyerburgDivision of Pulmonary, Allergy, and Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
William T HorneRichard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
Jose M LoraConstellation Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
Brian K AlbrechtConstellation Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
Joseph M PilewskiDivision of Pulmonary, Allergy, and Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
Jay K KollsRichard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
University of Pittsburgh Medical Center · USChildren's Hospital of Pittsburgh · USConstellation Pharmaceuticals (United States) · USChildren's Hospital of Philadelphia · USRichard King Mellon Foundation · USUniversity of Pittsburgh · US
Funding
Project 2 Impact of Innate and Adaptive Immunity At the Airway Epithelium in Severe AsthmaP01AI106684 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sally E Wenzel · 2015 to 2026
$18.9MTranslational StudiesP30DK072506 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PILEWSKI, JOSEPH MARK · 2005 to 2017
$12.5MTh17 Cytokines and Lung ImmunityR37HL079142 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KOLLS, JAY K · 2010 to 2017
$3.6MA Critical Role for Follistatin-like Protein-1 in Lung HomeostasisK08HL128809 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAMPFIELD, BRIAN T · 2015 to 2019
$675kAntigen discovery and validation in Pneumocystis pneumoniaF30AI114146 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI EDDENS, TAYLOR JOHN · 2014 to 2017
$189kNHLBI NIH HHS K08 HL128809NHLBI NIH HHS R37 HL079142NIAID NIH HHS F30 AI114146NIAID NIH HHS P01 AI106684NIDDK NIH HHS P30 DK072506
Abstract
Significant morbidity in cystic fibrosis (CF) results from chronic lung inflammation, most commonly due to
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.